Ireland
--:--IST
Active, not recruiting Observational

ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

NCT05653063 · tracked via the Priya Life Science India tracker
Phase
Observational
Started
2023-12-07
Last updated
2026-07-22

Condition(s) studied

Cancer of ProstateCancer Head NeckCancer Cervix

Investigational drug(s) / intervention(s)

A web-based artificial intelligence (AI) auto-planning tool

A web-based artificial intelligence (AI) auto-planning tool: The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically. In this study patients will not be treated with the AI tool but the manual plan created by the local teams.

Study summary

The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams.

The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy. 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy. 3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy. 4. Mental capacity to understand and consent to participate in the study. 5. Patients aged ≥18years. Exclusion Criteria: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible. 2. Patients receiving palliative radiotherapy 3. Patients aged \< 18years.

Primary outcome measure(s)

  • Proportion of radiotherapy treatment plans that have contours and dosimetry that meet pre-defined criteria for clinical acceptability — Prior to first treatment

Trial sites (6)

FacilityCityRegionStatus
Tata Medical Centre Kolkata India
Tata Memorial Hospital Mumbai India
King Hussein Cancer Center Amman Jordan
University of Malaya Medical Center Kuala Lumpur Malaysia
Groote Schuur Hospital Cape Town South Africa
Tygerberg Hospital Stellenbosch South Africa

More University College, London trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05653063 on ClinicalTrials.gov ↗ ← All trials in India